Table 1.
Simultaneous (de novo) combination therapy with NA and Peg-IFNα.
| Author (Year) |
HBeAg |
n (Genotype, %) |
Age * | Male (%) |
Regimens | HBV DNA Response (%) | Seroconversion of HBeAg (%) | Decline in HBsAg (log) | HBsAg Seroclearance (%) |
|---|---|---|---|---|---|---|---|---|---|
| Tangkijvanich et al. (2016) [26] | − | 63 (B16/C81) |
40 + 9.8 | 73 | 48-wk ETV + Peg-IFNα | 38.1% < 2000 IU/mL, 6.3% < 10 IU/mL | N.D. | −0.5 | 4.8% |
| Hagiwara et al. (2013) [27] |
+/− | 17 (C100) |
47 + 12 | 76 | 48-wk ETV + Peg-IFNα | 71% < 10,000 copies/mL at EOF | 73% at EOF | −0.4 | 5.9% |
| Hagiwara et al. (2018) [28] | +/− | 26 (C100) |
44 + 10 | 69 | 48-wk ETV + Peg-IFNα | 62% < 4.0 log copies/mL at EOF | 60% at EOF | N.D. | 15% |
| Marcellin et al. (2016) [29] |
+/− | 186 (A9/B27/C42/D21) |
38 + 17 | 68 | 48-wk TDF + Peg-IFNα | 9.1% < 15 IU/mL at wk 72 |
25% at wk 72 | −1.3 | 9.1% at wk 72 |
| Ahn et al. (2018) [30] |
+/− | 186 (A9/B27/C42/D21) |
38 + 17 | 68 | 48-wk TDF + Peg-IFNα | 24.3% < 15 IU/mL at wk 120 |
29.5% at wk 120 | −2.4 | 10.4% at wk 120 |
| Zheng et al. (2019) [31] |
+/− | 77 (N.D.) |
30 + 7.3 | 71 | 48-wk TDF + Peg-IFNα | 33.8% < 100 IU/mL at EOT |
34% at EOT | N.D. | 13% |
| de Niet et al. (2017) [32] |
− | 45 (A22/B7/C2/D29/E16) |
43 + 12 | 47 | 48-wk TDF + Peg-IFNα | N.D. | N.D. | −0.59 | 4% |
* Mean ± SD; EOF, end of follow up; EOT, end of treatment; ETV, entecavir; NA, nucleoside/nucleotide analogue; peg-IFNα, pegylated interferon-α; TDF, tenofovir disoproxil fumarate, N.D.; not described.